Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Keys to Fruitful Venture The board: Conveying Results on Time - 2Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- 3Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- 4How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- 5Home Security Frameworks with Shrewd Elements
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- Lego's $650 Pokémon set is already sold out as demand, preorders surge
- Merz says army could be involved in mine-clearing from Hormuz
- Vice President Dick Cheney’s life followed the arc of the biggest breakthroughs in cardiovascular medicine
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- Sustaining Public activity and Connections: Key Methodologies
- What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
